Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IIA Prostate Cancer Clear all
Completed Phase 2 Interventional Results available

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

NCT01882985
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Docetaxel, Lycopene
Drug · Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Not applicable Interventional

Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer

NCT03233555
View directory record Official record
Conditions
Stage I Breast Cancer, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Prostate Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage II Colorectal Cancer AJCC v7, Stage II Prostate Cancer, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer AJCC v7, Stage IIA Prostate Cancer, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer AJCC v7, Stage IIB Prostate Cancer, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7
Interventions
Informational Intervention, Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

NCT00033631
View directory record Official record
Conditions
Prostate Cancer
Interventions
70.2 Gy 3D-CRT/IMRT, 79.2 Gy 3D-CRT/IMRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
72
States / cities
Long Beach, California • Sacramento, California • San Francisco, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1 Interventional

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00026377
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, goserelin acetate, leuprolide acetate, SU5416, radiation therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Chicago, Illinois • LaGrange, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

NCT01535040
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder
Interventions
memantine hydrochloride, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jul 22, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional

Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00004050
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuvectin
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Jul 22, 2026, 2:10 AM EDT
Active, not recruiting No phase listed Observational

Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

NCT00769223
View directory record Official record
Conditions
Prostate Cancer, Radiation Toxicity
Interventions
medical chart review, questionnaire administration, quality-of-life assessment, brachytherapy, radiation therapy
Other · Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
3,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate CCS1477 in Advanced Tumours

NCT03568656
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
Interventions
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Terminated Phase 3 Interventional Results available

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

NCT00354432
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00004054
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

NCT00002874
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, radiation therapy, placebo
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Male only
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2022
U.S. locations
221
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Jul 22, 2026, 2:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

NCT01335204
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Cabazitaxel plus bavituximab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Jul 22, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer

NCT00814892
View directory record Official record
Conditions
Prostate Cancer
Interventions
allogeneic tumor cell vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Not applicable Interventional

Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer

NCT00045331
View directory record Official record
Conditions
Prostate Cancer
Interventions
proteomic profiling
Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

NCT01106352
View directory record Official record
Conditions
Bone Metastases, Castration-Resistant Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Not applicable Interventional

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

NCT02346253
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate, Goserelin Acetate, Triptorelin Pamoate, Degarelix, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Radiation · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
Male only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 2:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

NCT04868604
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
Drug
Lead sponsor
Clarity Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Stanford, California • River Ridge, Louisiana • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer

NCT01325311
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
Cholecalciferol, Genistein, Laboratory Biomarker Analysis, Pharmacological Study, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Baltimore, Maryland • Burlington, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Jul 22, 2026, 2:10 AM EDT
Terminated Phase 3 Interventional

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

NCT00005073
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Jul 22, 2026, 2:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

NCT03572478
View directory record Official record
Conditions
Prostate Cancer, Endometrial Cancer
Interventions
Rucaparib, Nivolumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Not applicable Interventional

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

NCT02163317
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
stereotactic radiosurgery, magnetic resonance imaging, quality-of-life assessment, Serum Prostate Antigen Test, Digital Rectal Exam, Expanded Prostate Cancer Index Composite
Radiation · Device · Other + 2 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Not applicable Interventional

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

NCT00433407
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
trastuzumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jul 22, 2026, 2:10 AM EDT
Active, not recruiting Not applicable Interventional

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

NCT02176902
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
behavioral dietary intervention, omega-3 fatty acid, laboratory biomarker analysis
Behavioral · Dietary Supplement · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Active, not recruiting Not applicable Interventional

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

NCT04985565
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
Interventions
Dietary Intervention, Radical Prostatectomy
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 22, 2026, 2:10 AM EDT